Insider Trends: Insider at Exelixis Gets Stock Award Makes Tax Sale with Portion, Easing 90-Day Buy Trend
10:52 PM EST, 02/05/2021 (MT Newswires) -- On Feb 03, 2021, Dr Peter Lamb, EVP, Scientific Strategy & CSO, awarded 80,663 shares in Exelixis (EXEL) and sold 19,997 shares concurrently to meet tax obligations. After accounting for tax obligations this transaction resulted in a net acquisition of 60,666 company shares. After the Form 4 filing with the SEC, Dr Lamb controls a total of 360,895 shares of the company, with 343,790 shares held directly and 17,105 owned indirectly. The market value of the direct and indirect holdings, based on the prior-day closing price, is approximately $8.27 million.
During the most recent 90-day period, prior to the date of this filing, there have been 27 insider transactions reported to the SEC for Exelixis. These transactions came from the activities of 8 separate insiders that resulted in a net acquisition of 192,529 company shares. In the preceding 90-day window of time, there were 28 transactions from 8 insiders and resulted in the net acquisition of 279,727 shares.
This level of insider transactions is below that of the peer group average in the 324-company Bio Therapeutic Drugs peer group over the last 90-day period. Peer group activity averaged 56.3 transactions per company, with company insiders acquiring on average 24,493 shares.
SEC Story Link http://www.sec.gov/Archives/edgar/data/939767/000093976721000012/xslF345X03/wf-form4_161257791484447.xml
This report does not constitute a recommendation to purchase or sell any security and the analysts are not registered investment advisors. Further analysis is recommended before undertaking any position in any security. Any risks are solely the responsibility of the buyer/seller. The authors, publishers and distributors of the MT Newswires Live Briefs service and any associates thereof accept no liability for the content or actions taken by anyone or institution utilizing this report.